Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Tiragolumab · RO7092284, MTIG-7192A

Monoclonal antibody · Antagonist of TIGIT · developed by Hoffmann-La Roche

Phase 1/2 Most advanced trial
2 Registered trials

What is Tiragolumab?

Tiragolumab is a human monoclonal antibody that binds TIGIT, a co-inhibitory immune checkpoint on T-lymphocytes and NK cells. By blocking TIGIT, it prevents inhibitory signaling and enhances costimulatory CD226 signaling, activating anti-tumor immune responses. It is studied in advanced liver cancer and gastroesophageal cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
RO7092284, MTIG-7192A, RG-6058
Drug type
Monoclonal antibody
Targets
TIGIT, CD112 (NECTIN2) (secondary target), CD155 (PVR) (secondary target), CD226 (secondary target)
Mechanism
Antagonist of TIGIT
Pathways
immune_activation, T-cell activation
Therapy area
Oncology
Developer
Hoffmann-La Roche
In trials of
ADAG, BLRX
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
6XG22YQM2Z

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04524871 Phase 1/2 Advanced Liver Cancers Active not recruiting ADAG
NCT03281369 Phase 1/2 Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or… Terminated BLRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Liver Cancers

Other drugs acting on TIGIT

BMS-986442 Phase 1 Dargistotug Phase 2 Domvanalimab Phase 2 Rilvegostomig Phase 3 TAB006 Phase 1

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.